How much of Pfizer's Q3 2024 revenue growth came from COVID products?

Paxlovid revenue of $2.7B rose $2.5B operationally, and Comirnaty revenue of $1.4B rose 9%. Together they drove most of the 32% operational growth. Excluding these two products, revenue grew 14% operationally, which indicates the underlying non-COVID business is growing at a healthy pace.

Did Pfizer's guidance change, and by how much?

Yes. Full-year 2024 revenue guidance was raised to $61.0–$64.0B from $59.5–$62.5B, a $1.5B increase at the midpoint. Adjusted diluted EPS guidance was raised to $2.75–$2.95 from $2.45–$2.65, a $0.30 increase at the midpoint. Guidance assumes no share repurchases and about 5.7 billion diluted shares.

Why did GAAP EPS differ from Adjusted EPS in Q3 2024?

GAAP Reported diluted EPS was $0.78, versus Adjusted EPS of $1.06. The gap mainly reflects amortization of intangible assets ($1.3B pre-tax), acquisition-related items, restructuring charges, and a $420M charge tied to the expected sale of a facility after the DMD program was discontinued. Pfizer also recorded net gains on equity securities that partly offset these items on a GAAP basis.

What did Pfizer do with its cash and capital in the first nine months of 2024?

Pfizer invested $7.8B in internal R&D and about $200M in business development, and paid $7.1B in cash dividends ($1.26 per share). It made no share repurchases year-to-date and has $3.3B remaining under its repurchase authorization. Guidance does not anticipate buybacks in 2024.

What are the main risks flagged in the release?

The release highlights the Oxbryta withdrawal and potential impact on sickle cell assets, the risk that COVID demand becomes more seasonal or declines, erosion from generic and biosimilar competition (Xeljanz, Ibrance), pricing pressure from the Inflation Reduction Act (including the Eliquis maximum fair price of $231 effective 2026), and the possibility that cost-reduction programs fail to deliver expected benefits.

PFE 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.

Pfizer reported third-quarter 2024 results on October 29, 2024, with revenues of $17.7 billion^a, up 31% reported and 32% operationally year-over-year, and raised full-year 2024 guidance for both revenue ($61.0 to $64.0 billion, previously $59.5 to $62.5 billion) and Adjusted diluted EPS ($2.75 to $2.95, previously $2.45 to $2.65).

The headline growth is flattered by Paxlovid ($2.7 billion^b, including a one-time $442 million Strategic National Stockpile delivery) and the year-over-year comparison against a $5.6 billion non-cash inventory write-off in Q3 2023. Management emphasized that excluding Paxlovid and Comirnaty, revenues grew 14% operationally, and that legacy Seagen, Vyndaqel, Eliquis, Xtandi and Nurtec were the main contributors, while Xeljanz and Ibrance declined. GAAP Reported diluted EPS was $0.78 for the quarter, compared with a loss of $0.42 a year earlier.

Adjusted diluted EPS was $1.06^c. Reported results benefited from a much lower cost of sales, which fell 43% to 29.7% of revenues, but were offset by a $420 million charge tied to the expected sale of a facility after Pfizer discontinued its Duchenne muscular dystrophy program, along with higher net interest expense from the Seagen financing. Management reiterated a target of at least $5.5 billion in net cost savings from its cost initiatives, including at least $4 billion by year-end 2024.

Capital returns were $7.1 billion^d in dividends for the first nine months, with no share repurchases year-to-date and none assumed in guidance. For investors, the key questions are the sustainability of COVID-product revenue after 2024, the pace of non-COVID growth, and whether the cost program produces the promised margin expansion.

The filing also notes the October 2024 sale of Haleon shares for about $3.5 billion, which reduces Pfizer's stake from roughly 23% to 15%, and the voluntary withdrawal of Oxbryta, which reduces sickle cell sales. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

02—Key points

Key Highlights

Q3 2024 revenue of $17.7B, up 31% reported and 32% operationally; excluding Paxlovid and Comirnaty, revenue grew 14% operationally to $13.6B.
Full-year 2024 revenue guidance raised to $61.0–$64.0B (midpoint up $1.5B), including ~$5B Comirnaty and ~$5.5B Paxlovid.
Adjusted diluted EPS guidance raised to $2.75–$2.95 (midpoint up $0.30); Q3 Adjusted EPS $1.06 vs. $(0.17) a year ago; GAAP Reported EPS $0.78.
Cost of sales fell 43% to $5.3B (29.7% of revenue) as Q3 2023 included a $5.6B non-cash inventory write-off; Adjusted cost of sales fell 45%.
Oncology and specialty growth led by Vyndaqel (+63% operationally), Xtandi (+28%), Nurtec (+45%), and legacy Seagen revenue of $854M; Xeljanz (-35%) and Ibrance (-12%) declined.
Pfizer sold Haleon shares for ~$3.5B in October 2024, reducing its stake from ~23% to ~15%.
Cost savings target of at least $5.5B on track, including at least $4B by end-2024; no share repurchases in 2024 and $3.3B remaining authorization.

03—Questions

Frequently Asked Questions

How much of Pfizer's Q3 2024 revenue growth came from COVID products?
Paxlovid revenue of $2.7B rose $2.5B operationally, and Comirnaty revenue of $1.4B rose 9%. Together they drove most of the 32% operational growth. Excluding these two products, revenue grew 14% operationally, which indicates the underlying non-COVID business is growing at a healthy pace.
Did Pfizer's guidance change, and by how much?
Yes. Full-year 2024 revenue guidance was raised to $61.0–$64.0B from $59.5–$62.5B, a $1.5B increase at the midpoint. Adjusted diluted EPS guidance was raised to $2.75–$2.95 from $2.45–$2.65, a $0.30 increase at the midpoint. Guidance assumes no share repurchases and about 5.7 billion diluted shares.
Why did GAAP EPS differ from Adjusted EPS in Q3 2024?
GAAP Reported diluted EPS was $0.78, versus Adjusted EPS of $1.06. The gap mainly reflects amortization of intangible assets ($1.3B pre-tax), acquisition-related items, restructuring charges, and a $420M charge tied to the expected sale of a facility after the DMD program was discontinued. Pfizer also recorded net gains on equity securities that partly offset these items on a GAAP basis.
What did Pfizer do with its cash and capital in the first nine months of 2024?
Pfizer invested $7.8B in internal R&D and about $200M in business development, and paid $7.1B in cash dividends ($1.26 per share). It made no share repurchases year-to-date and has $3.3B remaining under its repurchase authorization. Guidance does not anticipate buybacks in 2024.
What are the main risks flagged in the release?
The release highlights the Oxbryta withdrawal and potential impact on sickle cell assets, the risk that COVID demand becomes more seasonal or declines, erosion from generic and biosimilar competition (Xeljanz, Ibrance), pricing pressure from the Inflation Reduction Act (including the Eliquis maximum fair price of $231 effective 2026), and the possibility that cost-reduction programs fail to deliver expected benefits.

04—Continue

← View all 8-K filings